Senator John Cornyn @JohnCornyn
WSJ: Eli Lilly & Co., facing mounting scrutiny in the U.S. Congress over big increases in the list price of a widely used insulin, says the price it was paid dropped by 8.1% during the previous five years after accounting for rebates and discounts. — PolitiTweet.org